Gene transfer to central nervous system (CNS) has been approached using various vectors. Recombinant SV40-derived vectors (rSV40s) transduce human neurons and microglia effectively in vitro and in rodent brains in vivo, so we tested rSV40s gene transfer to rhesus monkey CNS in vivo, to characterize the distribution, duration and safety of such gene delivery. We used rSV40s carrying HIV-1 RevM10 with a carboxyl-terminal AU1 epitope tag as a marker, and others with the antioxidant enzymes, Cu/Zn superoxide dismutase and glutathione peroxidase. Vectors were injected stereotaxically into the caudate nucleus. Transgene expression was studied at 1 and 6 months by immunostaining serial brain sections. After intraparenchymal administration, numerous transgene-expressing cells were seen, with a longitudinal extent of 20 mm. In neurons and, more rarely, microglial cells, transgene expression remained strong throughout the 6-month study period. Astrocytes and oligodendroglia were not transduced. No evidence of inflammation or tissue damage was observed. SV40-derived vectors may thus be useful for long-term gene expression in the monkey brain and, potentially, in the human brain.
INTRODUCTION

Expression of therapeutic proteins may be useful in treating any number of diseases affecting the central nervous system (CNS).
Gene transfer to the CNS has been tested using several vectors, but each system has limitations, [1] [2] [3] [4] [5] [6] and the effectiveness of gene therapy for CNS diseases has so far been very limited. [7] [8] [9] [10] [11] [12] [13] [14] Recombinant T-antigen (Tag)-deleted SV40-derived viral vectors (rSV40s) provide efficient gene transfer and stable gene expression in vivo to different cell types, including neurons. [15] [16] [17] rSV40s transduce 495% of cultured human NT2 cells, primary neurons and microglia without detectable toxicity and requiring selection. [18] [19] [20] We have previously reported that SV40-derived vectors may thus be useful for longterm gene expression in the brain: both locally, by intraparenchymal administration, and diffusely, by intracerebroventricular injection. 21 Intracerebral or intraventricular injection of recombinant SV40 vectors carrying the antioxidant enzymes, Cu/Zn superoxide dismutase (SOD1) or glutathione peroxidase (GPx1), SV(SOD1) or SV(GPx1), significantly protected neurons from oxidative injury and apoptosis elicited by HIV-1 envelope glycoprotein, gp120 or Tat. [22] [23] [24] [25] Intracerebroventricular administration of SV(SOD1) or SV(GPx1), particularly if preceded by systemic mannitol, is protected from local gp120-induced neurotoxicity as well as did intraparenchymal administration of antioxidant enzymes to the site of subsequent challenge (490% protection). 24 Previous personal reports from our group have shown the transduction efficiency and distribution of rSV40 viral vectors in the rodent brain. Few studies have been carried out using non-human primates. The organization, complexity and size of the monkey brain are closer to the human brain, and assessing the effectiveness gene transfer in rhesus macaques may provide important information with regard to safety and efficacy, preparing for clinical trials. This study was designed to test localized rSV40 gene transfer to the CNS (caudate nucleus) of rhesus monkeys in vivo. The distribution and duration of transgene expression and cell types transduced were characterized. rSV40 vectors carrying either a marker transgene with an AU1 epitope, tag appended to a carrier protein, in this case HIV-RevM10, and another carrying SOD1 and GPx1 were used. An unrelated rSV40 vector, SV(BUGT), was used as an rSV40 control. Transgene expression was tested at different time points after vector injection by immunostaining and western blot analysis of brain sections.
RESULTS
Efficient transgene expression after intraparenchymal rSV40 injection
The distribution of transgene expression was studied by immunocytochemistry on cryostat sections of control uninjected rhesus macaques brains or brains whose caudates have been injected stereotaxically with SV(SOD1), SV(GPx1), SV(RevM10.AU1) or a control SV40 vector, SV(BUGT). In all, 10 8 infectious units (IU) of SV(GPx1) plus 10 8 IU of SV(SOD1), or 2Â10 8 IU of SV(RevM10.AU1) was injected by stereotaxic inoculation into one caudate in the rhesus macaques. A total of 2Â10 8 IU of control, SV(BUGT) was injected in both caudates. Numerous transgene-positive cells were observed at both assay times: 1 and 6 months after injection of SV(SOD1)/ SV(GPx1) or SV(RevM10.AU1) into the caudate (Figure 1b) . No AU1, SOD1 or GPx1 expression was observed in any section after injection of SV(BUGT) or in the control uninjected brain (Figure 1a) . Control sections incubated with non-immune primary antibody were negative (not shown). Western blot analysis carried out 1 and 6 months after vector injection showed expression of the delivered SOD1 on the side injected with SV(SOD1) (Figure 1c ).
Characterization of transduced cells after injection of rSV40 vectors into the caudate
To determine the cell types transduced by rSV40 vectors, we used immunocytochemistry to stain representative sections of brains harvested 1 and 6 months after injection of the rSV40s into the caudate. Sections of caudate were double-stained for the transgene SOD1 plus lineage markers (see Materials and Methods). More than 95% of transgene-expressing cells also stained positively for neuronal markers (NT or neuN), indicating substantial neuronal transduction. A few microglial cells (Iba-1 positive) expressed SOD1. Astrocytes generally did not express the transgene (Figure 2a) . No transgene-expressing oligodendrocytes were observed. Comparable results were observed for AU1 and GPx1 (not shown). Sections of caudates injected with SV(GPx1) and SV(SOD1) were immunostained for the respective Figure 1 Efficient transgene expression after injection of rSV40s into the monkey caudate nucleus. The distribution of transgene expression was studied by immunocytochemistry on cryostat sections of control uninjected rhesus macaque brains or brains whose caudates have been injected stereotaxically with SV(SOD1), SV(GPx1), SV(RevM10.AU1) or a control SV40 vector, SV(BUGT). In all, 10 8 IU of SV(GPx1) plus 10 8 IU of SV(SOD1), or 2Â10 8 IU of SV(RevM10.AU1) were injected by stereotaxic inoculation into one caudate in the rhesus macaques. A total of 2Â10 8 IU of control SV(BUGT) was injected in both caudates. (a) No transgene expression was observed in control uninjected brains or after injection of SV(BUGT). Nuclei were stained by 4¢,6-diamidino-2-phenylindole. (b) Numerous transgene-positive cells were observed 1 month after injection of SV(SOD1)/SV(GPx1) or SV(RevM10.AU1) into the caudate. Nuclei were stained by 4¢,6-diamidino-2-phenylindole. Control sections incubated with non-immune primary antibody were negative (not shown). (c) Western blot analysis carried out 1 and 6 months after vector injection showed overexpression of SOD1 on the injected side with SV(SOD1). SupT1 cells transduced with SV(SOD1) were a positive control; no signal was seen in the caudate injected with SV(BUGT). Glyceraldehyde-3-phosphatedehydrogenase was used as a loading control. CP1 inj. SV(SOD1): caudate was examined for transgene expression 1 month after SV(SOD1) injection; CP2 inj. SV(SOD1): caudate nucleus was examined for transgene expression 6 months post-SV(SOD1) inoculation; SupT1 TD SV(SOD1): SupT1 cells were transduced with SV(SOD1) and used as a positive control; and CP inj. SV(BUGT): caudate nucleus was injected with SV(BUGT) and examined 1 month after vector injection. Bar: (a, b), 60 mm; inset: 20 mm. transgene products; most of the cells positive for SOD1 were also positive for GPx1 (Figure 2b ).
High percentage of neurons expressed the transgenes in the caudate
The longitudinal extent of the transduced area for the different transgenes was studied on serial cryostat sections examined on 5-mm-thick slices of brain tissue, cut coronally. Transgene expression was seen from the most frontal to the most caudal areas, from the pre-commissural (Figure 3a) to the post-commissural area (Figure 3b ). The longitudinal extent of the transduced area for the different transgenes was at least 20 mm. At 1 month after the injection of the vector, the percentages of transgene-positive cells were almost similar, whatever the transgene assayed (percent of NT+ cells positive for: AU1, 25.2±3.4; SOD1, 26.5±2.9; GPx1, 26.1±3.6). Six months post-injection, the percents of transgene-positive cells were slightly greater than that at 1 month, possibly due to the accumulation of 
No large Tag in the brain or organs after intraparenchymal injection of rSV40 vectors
The rSV40 viral vectors we used were Tag-deleted, replication-defective SV40 vectors. We have never detected wild-type, Tag-expressing revertants in any of our preparation. However, to confirm that caudate nuclei and peripheral organs of rhesus macaques injected intracerebrally with rSV40 vectors were devoid of large Tag, we immunostained the caudate for large Tag and the organs for AU1 and large Tag. As a positive control, we used cultured COS-7 cells, which express large Tag. Brains and organs of rhesus macaques whose caudates had been injected with rSV40 vectors were completely immunonegative for large Tag (Figures 6 and 7) . Immunostaining for AU1 was negative in peripheral organs ( Figure 7) . No inflammation or microscope evidence of pathology was seen in any organ at either time point (Figure 7 ).
DISCUSSION
Gene transfer into the brain has been achieved using various viral vectors. Adenoviral-mediated gene transfer to the brain may achieve high levels of gene expression, but is limited by several factors. 1, 2 There are innate and acquired immune reactions against the virus, and against foreign transgenes as well. These host responses limit the duration of transient gene expression and eliminate transduced cells. 26 The development of gutted vectors, manipulation of host immune response and use of less immunogenic transgenes have all been used to try to circumvent these limitations. However, success to date has been limited. 27 Comparable problems were observed during adenovirusmediated gene transfer to the CNS of rhesus monkeys: transgene expression was variable and declined over time, 28, 29 in part due to inflammatory responses to adenovirus-transduced cells. 30 Vectors derived from adeno-associated viruses (AAV) elicit little, if any, damage or inflammatory response after intracerebral injection, and may deliver long-term transgene expression to non-dividing cells in multiple tissues, including the brain in rodents and in monkeys. [31] [32] [33] [34] [35] [36] [37] [38] However, the size of the transgene inserted must be smaller than 4 kb. AAV tropism and transduction efficiency can be modified by using different AAV serotypes. [39] [40] [41] Lentiviral vectors can transduce some postmitotic cells, including neurons. Gene transfer to the rodent and primate CNS in vivo has been shown with lentiviral vectors derived from HIV and other lentiviruses. 3, 4, 8, [42] [43] [44] HSV type 1 multigene vector safety and biodistribution have also been studied in non-human primate brain. 45 In non-human primates, CNS transduction efficiency and durability varied with the vector, injection site and method of delivery. For AAV vectors, transduced cells numbered from 444 400 at 8 weeks to 1 296 350 at 3 years, 32 for lentiviral vectors, 764 149 at 1 month for lentiviral vectors 42 titers ranging between 2.75Â10 12 genome copies per ml for AAV2/1, 1.69Â10 13 42 and between 2Â10 10 PFU ml À1 (ref. 30 ) and 2Â10 9 PFU ml À1 (ref. 29 ) for adenoviral vectors. Moreover, several vector injections were carried out in the same structure in some of these studies. 32, 42 In this study, a single injection of 10 8 rSV40 vectors transduced between 1 500 000 and 1 800 000 cells, almost all of them neurons, in the caudate nucleus, respectively, 1 and 6 months after injection.
We used rSV40 vectors here to deliver different transgenes, including potentially useful therapeutic gene into the brain, because they transduce many cell types, including neurons, in G 0 with high efficiency and integrate into their genomes to provide permanent transgene expression. We observed efficient, sustained gene transfer to the monkey CNS: injection into the caudate resulted in large numbers of cells expressing the transgene. The estimated number of cells that expressed each of the rSV40-delivered transgene slightly exceeds the numbers reported using AAV2, which is perhaps the best rAAV reported so far for transducing the striatum of monkey. 32 Further, the doses of rSV40s needed to achieve these results are several orders of magnitude less than the doses of rAAV2s used to achieve comparable numbers of transduced cells. Transgene expression continued undiminished for the 6 months duration of these studies, which is characteristic of these vectors. [15] [16] [17] In this study, rSV40 vectors were effective in transducing both primate neurons and microglia, which parallels findings in rodent brains in vivo and in cultured human cells. [18] [19] [20] Again, as in other studies, 18 Unlike adenoviruses, rSV40s characteristically do not elicit inflammatory responses in the CNS or elsewhere. 15 Current studies document the lack of detectable immune or inflammatory reaction to the vector and the transgene delivered here. In addition, rSV40s do not elicit detectable immune responses. 46 They may thus be administered multiple times. Although this study did not include repeat administrations, it is possible to increase numbers of transduced cells above what we report here by using multiple inoculations of rSV40s. This approach has been successful in increasing numbers of rSV40-transduced cells in studies in vivo targeting other organs, 47, 48 and this unique advantage characteristic of rSV40s allows for multiple consecutive administrations, either in rapid sequence or with lengthy time intervals in between without the loss of gene delivery efficiency. 49 In addition to increasing numbers of transduced cells by multiple administrations, it is possible to broaden the distribution of gene delivery using different routes of administration.
We reported in vivo transduction of neurons by rSV40 vectors by intra-CSF (intraventricular) injection. 21 Moreover, systemic mannitol administration dramatically improved transgene expression and the therapeutic effect tested (protection from oxidant injury). Furthermore, even intravenous rSV40s' administration, when combined with systemic mannitol injection, provides excellent, widespread gene transfer throughout the CNS. 50 We have shown that rSV40s are highly effective and safe gene delivery vehicles for transducing neurons in the brains of non-human primate. At doses orders of magnitude lower than are needed for other vectors, rSV40s deliver permanent and safe transgene expression. They may thus merit consideration for experimental and therapeutic application in primates and, potentially, human beings. 
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MATERIALS AND METHODS Animals
Female Macaca mulatta (3.04-3.53 years old; 4.10-5.05 kg) were bred and raised at the Tulane National Primate Research Center. Protocols for injecting and euthanizing animals were approved by the Tulane National Primate Research Center Institutional Animal Care and Use Committee and are consistent with Association for Assessment and Accreditation of Laboratory Animal Care standards. The diet that the animals received was a regular standard commercial diet, regular diet without any component that might cause oxidative stress (such as high fat diet or high manganese) and was not folate/methyl or iron deficient. Monkeys had free access to water and diet. Numbers of animals used in experiments are indicated in the 'Experimental design' section.
Antibodies
Different primary antibodies were used: fluorescein isothiocyanate (FITC)-conjugated mouse anti-AU1 (IgG2a; 1:100; Covance, Emeryville, CA, USA), rabbit anti-Iba1, a marker of quiescent and active microglia (IgG; 1:100; Waco Chemicals, Osaka, Japan), mouse anti-CD8a (IgG1 k, 1:100), mouse anti-CD68, a marker of activated microglia/mononuclear phagocyte (IgG1 k, 1:100), mouse anti-glial fibrillary acidic protein (IgG2b; 1:100) (Becton Dickinson Pharmingen, Franklin Lakes, NJ, USA), mouse anti-NeuN (IgG1; 1:100), mouse anti-oligodendrocyte (IgG1; 1:100) (Chemicon International, Temecula, CA, USA), rabbit anti-human SOD1 (1:100; Assay Designs, Ann Harbor, MI, USA) and mouse anti-GPx1 (IgG1k; 1:100; Abnova, Taipei City, Taiwan). Secondary antibodies were used at 1:100 dilution: FITC-and tetramethyl rhodamine isothiocyanate-conjugated goat anti-mouse, tetramethyl rhodamine isothiocyanate-conjugated goat anti-rabbit, FITC-conjugated sheep anti-rabbit (Sigma, Saint Louis, MO, USA), FITC-and tetramethyl rhodamine isothiocyanate-conjugated donkey anti-mouse IgG (whole molecule), FITC-and tetramethyl rhodamine isothiocyanate-conjugated donkey anti-rabbit IgG (whole molecule), and FITC-and Cy3-conjugated donkey anti-goat IgG (whole molecule) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).
Vector production
The general principles for making recombinant, Tag-deleted, replicationdefective SV40 viral vectors have been reported previously. 46, 49 The cloned rSV40 genome was excised from its carrier plasmid, gel-purified and recircularized, and then transfected into COS-7 cells. These cells supply in trans large Tag and SV40 capsid proteins, which are needed to produce recombinant replication-defective SV40 viral vectors. 17 SOD1 and GPx1 transgenes were subcloned into pT7[Rous sarcoma virus long-terminal repeat], in which transgene expression is controlled by the Rous sarcoma virus long-terminal repeat as a promoter. SV(RevM10.AU1) carries a dominant-negative mutant of HIV-1 Rev (RevM10), to which a carboxyl-terminal AU1 epitope tag was appended, and that was driven by the cytomegalovirus immediate-early promoter. The latter vector inhibits both HIV-1 and SIV. Crude virus stocks were prepared as cell lysates, and then band-purified by discontinuous sucrose density gradient ultracentrifugation and titered by quantitative PCR (Stratagene Inc., San Diego, CA, USA). 51 SV(BUGT) carries human bilirubin-uridine 5¢-diphosphate-glucuronosyl-transferase, which was used here as negative control vector, with a non-toxic byproduct, as has been reported. 52 
Transduction of SupT1 cells with SV(SOD1)
SupT1 cells are immortalized human T cells. They were grown in RPMI-1640 medium, and then they were transduced with SV(SOD1) and used as positive control for western blot analysis of SOD1 transgene expression.
Experimental design
Injection of SV40-derived vectors into the caudate. SV(SOD1), SV(GPx1), SV(RevM10) or a control SV40 vector, SV(BUGT) were injected into the caudate nucleus in M. mulatta. One control animal received 2Â10 8 IU of a control rSV40, SV(BUGT), into each caudate nucleus. Two normal rhesus macaques received 10 8 IU of SV(GPx1) plus 10 8 IU of SV(SOD1) in 0.01 ml by one stereotaxic inoculation into one caudate, and 2Â10 8 IU of SV (RevM10.AU1) into the opposite caudate nucleus. The control monkey and one test monkey were euthanized at 1 month and the other test monkey was killed at 6 months. In addition, caudate nuclei from two uninjected monkeys were used as controls.
In vivo transduction
Rhesus macaques were anesthetized with ketamine (10 mg kg À1 intramuscularly) and maintained with isoflurane and oxygen. They were placed in a stereotaxic head frame (Kopf Instruments, Tujunga, CA, USA) for cranial surgery. The manipulators and pumps used were by World Precisions Instruments (Sarasota, FL, USA). Monkeys were monitored with pulse oximetry, blood pressure, heart rate, respiration and CO 2 output. Body temperature was maintained at 37 1C with a Bair Hugger and warm recirculating water blanket. Animals were administered cefazolin intravenously at the beginning of surgery and every 2 h during the procedure. Vectors were injected into the caudate using Hamilton glass syringes (50 ml). For injection into the caudate nucleus, a burr hole was placed 3.0 mm posterior to bregma and 5.0 mm lateral to the sagittal suture. Once centered, the syringe was placed 15.0 mm ventral from the top of the brain. Following surgery, animals were housed individually with free access to water and food.
After a variable survival period, rhesus macaques were anesthetized via intraperitoneal injection of sodium pentobarbital (Abbott Laboratories, North Chicago, IL, USA) at 50 mg kg À1 . The rhesus macaques' brains and organs were then removed. The organs harvested included liver, kidney, heart, lung, spleen, bone marrow, ovaries, thyroid, pancreas, esophagus, stomach, intestine, adrenals and abdominal lymph nodes. For each brain and organ, half the samples were flash frozen, the other half was placed in 4% paraformaldehyde for 24 h, then in 30% sucrose for 24 h and finally frozen in methyl butane that had been cooled in liquid nitrogen. The samples were cut on a cryostat (10 mm sections). 
Immunocytochemistry
For immunofluorescence, coronal cryostat sections (10 mm thick) were processed for indirect immunofluorescence. Blocking was performed by incubating 60 min with 10% goat, or 10% donkey, serum in phosphate-buffered saline (PBS; pH 7.4). Then, sections were incubated with antibodies diluted according to the manufacturer's recommendations: 1 h with primary antibody, then 1 h with secondary antibody diluted 1/100, all at room temperature. Double immunofluorescence was performed as described previously. 53 All incubations were followed by extensive washing with PBS. Mounting media contained 4¢,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) to stain the nuclei. Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). Negative controls consisted of preincubation with PBS and 0.1% bovine serum albumin, substitution of non-immune isotype-matched control antibody for primary antibody and/ or omission of the primary antibody.
Staining of neurons using Neurotrace
To identify neurons and stain neurons, we used Neurotrace (NT), a fluorescent stain that has been applied as a neuronal marker in numerous studies focusing on the characterization of neurons, [54] [55] [56] and NT staining was performed as reported previously. 21, 22, 24, 57 After rehydration in 0.1 M PBS, pH 7.2, sections were treated with PBS plus 0.1% Triton X-100 10 min, washed twice for 5 min in PBS and then stained by NT (Molecular Probes Inc., Eugene, OR, USA) (1:100) for 20 min at room temperature. Sections were washed in PBS plus 0.1% Triton X-100, then 2Â with PBS and finally let to stand for 2 h at room temperature in PBS before being counterstained with 4¢,6-diamidino-2-phenylindole. Combination NT+ antibody staining was performed using primary and secondary antibodies staining first (see above), followed by staining with NT. Experiments were repeated three times and were carried out the same day for the different sections considered.
General morphology
Microscopic morphology of the brain was assessed by H&E staining of cryostat sections.
Morphometry
A computerized imaging system (Image-Pro Plus, MediaCybernetics, Bethesda, MD, USA) was used to quantitate transgene-positive cells manually. Transduction was assessed for each caudate nucleus 1 and 6 months after injection by serial cryo-sectioning of the sample (10-mm-thick coronal sections), each slide being numbered, and then by immunostaining of every 10th section for the transgene (that is, at 100-mm intervals). Because a total count of cells in each section was feasible, stereological sampling methods were not used. The total number (and not the number in random areas) of transgene-positive cells in one sample for every 10th section was counted and summed. The number presented for a particular level (that is, pre-commissural, commissural, postcommissural) was an average of the results measured in the different sections examined. The total number of positive cells in a caudate could be estimated by 'multiplying' the cell counts by the length of the transduced area, assuming the number of positive cells in the sections spanned between first and 10th one, for example, to be close to the numbers identified on these first and 10th sections. This procedure, already described for the assessment of numbers of transgenepositive cells in the brain, 7, 21 allows quantitative and relative comparisons among different time points, although it does not reflect the total number of transduced cells in vivo. However, if these calculations of cell counts do not Figure 7 Organs of rhesus macaques whose caudates have been injected with rSV40 vectors immunostained for large Tag and the transgene AU1. Organs were stained by H&E and immunostained for large Tag and the transgene AU1. No inflammation was seen in the organs stained by H&E. Immunostaining for AU1 and large Tag was negative in the organs examined. BM, bone marrow; esophag, esophagus; LN, abdominal lymph nodes. Bar: 100 mm.
conform to unbiased stereological method, they have been realized on 10-mmthick sections and the total number of positive cells has been counted in each section. Moreover, we used our current method for evaluating total numbers of neurons in the rat normal striatum using immunocytochemistry (using antiNeuN antibodies) and staining of neurons by NT. Preliminary results showed a total number of neurons close to the one measured using the optical fractionator method (not shown). Moreover, the number of transgene-expressing cells per brain section after rSV40 vector injection in the caudate was expressed as a percentage of the NT-positive cells in some experiments.
Western blot analysis
Brain sections were homogenized in buffer containing protease inhibitors and DNAse. Lysates were prepared as reported previously. 22 Total protein was estimated using BCA protein assay kit (Pierce, Rockford, IL, USA). Total cell proteins (100 mg) were loaded in each well, and then transferred to Immobilon-P poly vinylidine difluoride membrane (Millipore Inc., Billerica, MA, USA). Equal lane loading was assessed by using anti-glyceraldehyde-3-phosphate-dehydrogenase antibody (1:5000). The blot was realized according to manufacturer's instructions (Roche, Indianapolis, IN, USA). Anti-SOD1 antibody was used at a dilution of 1:500 and anti-rabbit horseradish peroxidase was used at a dilution of 1:5000 before the addition of chemoluminescence substrate (Roche). Positive control consisted of SupT1 cells transduced with SV(SOD1) and negative control was the caudate injected with SV(BUGT).
Statistical analysis
Results were expressed as average±s.e.m. Comparison of medians between two groups was achieved by using the Mann-Whitney test (with a two-tailed P-value). Comparison of medians between more than two groups was carried out by using the Kruskall-Wallis test. Comparison of two percentages was realized by using the Fisher's exact test (with a two-sided P-value). The difference between the groups was considered significant when Po0.05.
